These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28881380)

  • 21. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
    Nelson HD; Huffman LH; Fu R; Harris EL;
    Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
    Long KC; Kauff ND
    Curr Opin Oncol; 2011 Sep; 23(5):526-30. PubMed ID: 21734577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
    De Jaeghere E; Vandecasteele K; Claes K; Makar A; Tummers P; Cocquyt V; Denys H
    Acta Clin Belg; 2017 Feb; 72(1):6-11. PubMed ID: 27267353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
    Banerjee S; Kaye S
    Curr Oncol Rep; 2011 Dec; 13(6):442-9. PubMed ID: 21913063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients.
    Landsbergen K; Verhaak C; Kraaimaat F; Hoogerbrugge N
    Fam Cancer; 2005; 4(2):115-9. PubMed ID: 15951961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
    Rahman B; Lanceley A; Kristeleit RS; Ledermann JA; Lockley M; McCormack M; Mould T; Side L
    J Med Genet; 2019 Mar; 56(3):195-198. PubMed ID: 29535157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UK BRCA mutation testing in patients with ovarian cancer.
    George A
    Br J Cancer; 2015 Dec; 113 Suppl 1(Suppl 1):S17-21. PubMed ID: 26669451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic testing for epithelial ovarian cancer.
    Amin N; Chaabouni N; George A
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():125-138. PubMed ID: 32122773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system.
    Bellcross CA; Peipins LA; McCarty FA; Rodriguez JL; Hawkins NA; Hensley Alford S; Leadbetter S
    Genet Med; 2015 Jan; 17(1):43-50. PubMed ID: 24946155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
    Armstrong J; Toscano M; Kotchko N; Friedman S; Schwartz MD; Virgo KS; Lynch K; Andrews JE; Aguado Loi CX; Bauer JE; Casares C; Bourquardez Clark E; Kondoff MR; Molina AD; Abdollahian M; Walker G; Sutphen R
    JAMA Oncol; 2015 Dec; 1(9):1251-60. PubMed ID: 26426480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
    Paluch-Shimon S; Cardoso F; Sessa C; Balmana J; Cardoso MJ; Gilbert F; Senkus E;
    Ann Oncol; 2016 Sep; 27(suppl 5):v103-v110. PubMed ID: 27664246
    [No Abstract]   [Full Text] [Related]  

  • 35. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
    Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
    [No Abstract]   [Full Text] [Related]  

  • 36. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
    Kwon JS; Daniels MS; Sun CC; Lu KH
    J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.
    Meyer LA; Anderson ME; Lacour RA; Suri A; Daniels MS; Urbauer DL; Nogueras-Gonzalez GM; Schmeler KM; Gershenson DM; Lu KH
    Obstet Gynecol; 2010 May; 115(5):945-952. PubMed ID: 20410767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    Gori S; Barberis M; Bella MA; Buttitta F; Capoluongo E; Carrera P; Colombo N; Cortesi L; Genuardi M; Gion M; Guarneri V; Incorvaia L; La Verde N; Lorusso D; Marchetti A; Marchetti P; Normanno N; Pasini B; Pensabene M; Pignata S; Radice P; Ricevuto E; Sapino A; Tagliaferri P; Tassone P; Trevisiol C; Truini M; Varesco L; Russo A;
    Crit Rev Oncol Hematol; 2019 Aug; 140():67-72. PubMed ID: 31176273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    Hull LE; Haas JS; Simon SR
    Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.